First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

November 24, 2017: By Jon Swedien

Nevakar announced Nov. 21 that the first subject has been dosed in its Phase III clinical trial of NVK-002 for myopia in children.

NVK-002 is a topical ophthalmic solution intended to slow the progression of myopia in children. If it receives US FDA approval, NVK-002 would be the first pharmacologic eye drop for this patient population, Nevakar said.

The Phase III trial will enroll about 500 subjects ages 3 to 17 who have myopia spherical equivalent refraction (SER) of at least -0.50 diopters and no greater than -6.00 diopters in each eye. The three-arm, randomized, multicenter, double-masked, placebo-controlled trial will be conducted in two stages.

The first will evaluate the safety and efficacy of two concentrations (low dose and high dose) of NVK-002 compared with placebo for slowing progression of myopia over a three-year period. The second stage will be a randomized cross-over phase of one year in duration.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT